Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.

Also called NCT04004793

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 328 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04004793
Other papers using this trial's data
  • Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial BMJ (Clinical research ed.), 2025-01-22 DOI, PubMed 39843169, PMC11752448 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04004793. Randomized; triple masking; primary purpose treatment. Start 2020-06-12 (actual); primary completion 2023-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
Acronym
READ
Intervention (Behavioral)
Intensive lifestyle intervention
Intervention (Drug)
Dapagliflozin 10 MG Oral Tablet
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Shanghai Zhongshan Hospital (class: other)

Record details

Record id
cardio:ct-nct04004793
Content hash
e512ac4c1f850121889dbd4d5531af46af5b6c7c8a22d5358320c750d95d7b12